SOUTH SAN FRANCISCO, Calif., September 22, 2025 ‒ Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today announced that Fierce Biotech has named it as one of 2025’s “Fierce 15” biotechnology companies. This annual recognition celebrates 15 early-stage private companies that are pushing science and medicine forward with the industry’s most innovative and promising approaches. 

“At Trace Neuroscience, we have a fierce urgency to change the outlook for people with ALS who still lack effective therapies,” said Eric Green, M.D., Ph.D., co-founder and CEO of Trace Neuroscience. “As leaders in developing therapies to restore UNC13A—a critical protein in the nervous system—we are advancing a new class of medicines with transformative potential in neurodegenerative disease. We are grateful for this recognition and look forward to sustaining our momentum as we move into the clinic next year.” 

UNC13A is a genetic target directly linked to disease progression and survival in people with ALS, or amyotrophic lateral sclerosis. Approximately 97% of ALS patients produce insufficient amounts of UNC13A, which causes a breakdown in communication between nerve and muscle cells and leads to decreased mobility, difficulty breathing and paralysis. Trace Neuroscience’s lead program is an antisense oligonucleotide (ASO) designed to bind directly to UNC13A mRNA to regulate its processing and ensure proper splicing. UNC13A restoration shows promise in slowing disease progression, preserving or restoring function and extending survival in ALS and potentially other neurodegenerative diseases with similar pathology. 

About Fierce Biotech

Fierce Biotech is the industry’s daily report, covering the biopharma waterfront from drug development through the entire lifecycle—tracking regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation, M&A deals and beyond. Every year, Fierce Biotech evaluates hundreds of early-stage companies from around the world for its Fierce 15 list, which is based on a variety of factors such as the strength of a company’s technology, partnerships, venture backers and competitive market position.

About Trace Neuroscience

Trace Neuroscience is a biopharmaceutical company on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases. With an initial focus on ALS, the company is developing novel therapies to restore UNC13A protein function to re-establish healthy communication between nerves and muscle cells. Trace Neuroscience launched in 2024 with funding from Third Rock Ventures and other leading life sciences investors, and is headquartered in South San Francisco, CA. For more information, please visit us at www.traceneuro.com and follow us on LinkedIn and X. 

Media Contact:
Katie Engleman
[email protected]